Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) had its target price reduced by Citigroup from $136.00 to $131.00 in a report released on Tuesday,Benzinga reports. Citigroup currently has a buy rating on the stock. A number of other equities analysts have also issued reports on RYTM. Telsey Advisory Group set a $143.00 price objective on Rhythm […]

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) had its price objective increased by equities researchers at Piper Sandler from $219.00 to $232.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the specialty pharmaceutical company’s stock. Piper Sandler’s price target indicates a potential upside […]

Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) had its price objective lowered by Citigroup from $136.00 to $131.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Citigroup’s target price points to a potential upside of 45.83% from the company’s current price. Several other equities research […]

Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) had its target price increased by Oppenheimer from $53.00 to $57.00 in a research report report published on Tuesday,Benzinga reports. The brokerage currently has an outperform rating on the biopharmaceutical company’s stock. A number of other equities research analysts have also issued reports on the company. Royal Bank Of […]

Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) had its target price hoisted by Deutsche Bank Aktiengesellschaft from $56.00 to $90.00 in a research note released on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. Other equities analysts have also issued research reports about the stock. Bank of America reiterated […]

Eyepoint Pharmaceuticals (NASDAQ:EYPT – Free Report) had its price objective lifted by Citigroup from $31.00 to $35.00 in a report published on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the stock. A number of other research firms have also weighed in on EYPT. HC Wainwright upped their price objective on Eyepoint […]

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its target price upped by investment analysts at Morgan Stanley from $570.00 to $596.00 in a research note issued on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the pharmaceutical company’s stock. Morgan Stanley’s price target indicates a potential upside of 19.06% from the company’s […]

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price target boosted by analysts at Citigroup from $575.00 to $585.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the pharmaceutical company’s stock. Citigroup’s price target would indicate a potential upside of 15.52% from the stock’s […]